ArticlePhotochemistry and photobiology
Selectivity and anti-tumor immune elevation by vascular-targeted photodynamic therapy of mouse orthotopic bladder cancer model.
Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhanced survival through repeated photodynamic therapy and almost complete tumor regression by prior radiation therapy in an orthotopic rat bladder cancer model.Cancer cell international · 2026Article
- Selectivity and anti-tumor immune elevation by vascular-targeted photodynamic therapy of mouse orthotopic bladder cancer model.Photochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Vascular-targeted photodynamic therapy (VTP) with WST11 is a non-surgical tumor ablation approach that is currently being tested in a phase 3 clinical trial for the treatment of upper tract urothelial cancer. WST11-VTP utilizes illumination, leading to hypoxia, and production of free radicals followed by coagulative necrosis. Here, we tested the hypothesis that WST11-VTP can safely ablate muscle-invasive MB-49- luc bladder tumors in an orthotopic mouse model while sparing the surrounding normal tissue. For the safety study, normal mouse bladders were WST11-VTP treated. Fourteen days post-VTP granulomas in local areas around the ablation zone were noticed, which recovered after 44 days. MB49-luc orthotopic tumors at the muscle-invasive stage appeared to be effectively ablated by VTP 4-10 days post-treatment. The anti-tumor response was reflected in the increased invasion of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.